The new relationship is designed to provide Scirex with immediate access to well developed expertise in clinical investigation in India whilst giving Clinigene the opportunity to expand its markets and partake in global clinical trial programs.
Scirex CEO Jim Utterback said: “This brings our clients a best in class firm that not only offers them substantial value based on cost efficiencies and great science but also demonstrated clinical trial expertise. Scirex and our parent Omnicom Group can be truly integrated research and commercialization partners with Clinigene for years to come.”
Although the exact nature of the research was undisclosed, Dr Arvind Atignal, chief operating officer at Clinigene said the partnership would help further the position of both companies as world-class clinical development organizations.